U.S. FDA Pushes for More Blinding in Medtech Pivotal Trials

International Medical Device Regulatory Monitor
Devicemakers seeking regulatory approval in the U.S. are strongly urged to blind patients and investigators in pivotal clinical trials, when possible, according to final guidance issued by the Food and Drug Administration.

To View This Article:


Buy This Article Now

Add this article to your cart for $40.00